Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Coloplast A/S (COLO-B.CO)
Humlebæk, DK
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.92% | -2.49% | -7.10% | -18.28% | -32.21% | -25.56% | -37.76% | -56.60% | -59.11% | -19.72% | +227.30% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 13 | 0 |
| Sell | 4 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+3.1% Q1'26: +2.2% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-28.2% Q1'26: -206.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+10.4% Q1'26: +15.0% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+25.1% ★ Q1'26: +25.4% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+11.1% ★ Q1'26: +15.6% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+0.2% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×2.72× Q1'26: 1.18× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 15 Rev. Ana. 13 EPS Ana. |
Sep 2027 19 Rev. Ana. 16 EPS Ana. |
Sep 2028 18 Rev. Ana. 14 EPS Ana. |
Sep 2029 16 Rev. Ana. 6 EPS Ana. |
Sep 2030 9 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.91B
est: 13.91B (0.0%)
|
14.68B
est: 14.76B (-0.5%)
|
15.53B
est: 15.60B (-0.5%)
|
16.45B
est: 16.58B (-0.8%)
|
17.94B
est: 17.91B (+0.1%)
|
18.54B
est: 18.62B (-0.4%)
|
19.43B
est: 19.36B (+0.3%)
|
22.58B
est: 22.55B (+0.1%)
|
24.50B
est: 25.53B (-4.0%)
|
27.03B
est: 26.98B (+0.2%)
|
27.87B
est: 27.99B (-0.4%)
|
28.78B
28.38B – 28.99B
+2.8% YoY
|
30.79B
30.25B – 31.26B
+7.0% YoY
|
32.85B
32.82B – 32.88B
+6.7% YoY
|
35.27B
34.70B – 35.66B
+7.4% YoY
|
38.05B
37.44B – 38.48B
+7.9% YoY
|
| EBITDA |
1.76B
est: 4.50B (-60.8%)
|
4.65B
est: 4.77B (-2.5%)
|
5.61B
est: 5.04B (+11.2%)
|
5.68B
est: 5.36B (+5.9%)
|
5.69B
est: 5.79B (-1.8%)
|
6.35B
est: 6.02B (+5.4%)
|
7.08B
est: 6.26B (+13.2%)
|
7.23B
est: 7.29B (-0.8%)
|
7.73B
est: 8.25B (-6.3%)
|
8.57B
est: 8.72B (-1.8%)
|
8.34B
est: 9.05B (-7.9%)
|
9.30B
9.17B – 9.37B
+2.8% YoY
|
9.95B
9.78B – 10.11B
+7.0% YoY
|
10.62B
10.61B – 10.63B
+6.7% YoY
|
11.40B
11.22B – 11.53B
+7.4% YoY
|
12.30B
12.10B – 12.44B
+7.9% YoY
|
| EBIT |
1.25B
est: 3.88B (-67.8%)
|
4.09B
est: 4.12B (-0.6%)
|
4.96B
est: 4.35B (+14.0%)
|
5.05B
est: 4.63B (+9.2%)
|
5.03B
est: 5.00B (+0.8%)
|
5.50B
est: 5.19B (+5.8%)
|
6.26B
est: 5.40B (+15.9%)
|
6.30B
est: 6.29B (+0.2%)
|
6.66B
est: 7.12B (-6.4%)
|
7.31B
est: 7.52B (-2.9%)
|
6.98B
est: 7.81B (-10.6%)
|
8.03B
7.91B – 8.08B
+2.8% YoY
|
8.59B
8.44B – 8.72B
+7.0% YoY
|
9.16B
9.15B – 9.17B
+6.7% YoY
|
9.84B
9.68B – 9.95B
+7.4% YoY
|
10.61B
10.44B – 10.73B
+7.9% YoY
|
| Net Income |
899.00M
est: 3.47B (-74.1%)
|
3.14B
est: 3.97B (-20.9%)
|
3.80B
est: 4.13B (-8.0%)
|
3.85B
est: 4.16B (-7.7%)
|
3.87B
est: 4.52B (-14.4%)
|
4.20B
est: 4.53B (-7.3%)
|
4.83B
est: 5.19B (-7.0%)
|
4.71B
est: 5.37B (-12.4%)
|
4.78B
est: 4.97B (-3.7%)
|
5.05B
est: 5.16B (-2.2%)
|
3.64B
est: 4.78B (-23.9%)
|
3.66B
3.58B – 5.92B
-23.3% YoY
|
5.97B
5.52B – 6.41B
+63.1% YoY
|
6.48B
5.67B – 6.94B
+8.5% YoY
|
7.39B
7.24B – 7.50B
+14.1% YoY
|
7.90B
7.73B – 8.01B
+6.8% YoY
|
| SGA |
4.56B
est: 4.84B (-5.7%)
|
4.69B
est: 5.13B (-8.6%)
|
4.99B
est: 5.42B (-7.9%)
|
5.37B
est: 5.77B (-6.8%)
|
5.96B
est: 6.23B (-4.3%)
|
6.08B
est: 6.47B (-6.1%)
|
6.25B
est: 6.73B (-7.2%)
|
7.80B
est: 7.84B (-0.5%)
|
8.63B
est: 8.88B (-2.7%)
|
10.07B
est: 9.38B (+7.3%)
|
9.66B
est: 9.73B (-0.8%)
|
10.01B
9.87B – 10.08B
+2.8% YoY
|
10.71B
10.52B – 10.87B
+7.0% YoY
|
11.42B
11.41B – 11.43B
+6.7% YoY
|
12.26B
12.07B – 12.40B
+7.4% YoY
|
13.23B
13.02B – 13.38B
+7.9% YoY
|
| EPS |
4.30
est: 15.39 (-72.1%)
|
14.85
est: 17.63 (-15.8%)
|
17.91
est: 18.31 (-2.2%)
|
18.12
est: 18.48 (-1.9%)
|
18.24
est: 20.07 (-9.1%)
|
19.74
est: 20.08 (-1.7%)
|
22.67
est: 23.02 (-1.5%)
|
22.15
est: 23.84 (-7.1%)
|
22.21
est: 22.42 (-0.9%)
|
22.46
est: 22.99 (-2.3%)
|
16.13
est: 21.25 (-24.1%)
|
25.08
15.90 – 26.26
+18.0% YoY
|
26.77
24.48 – 28.44
+6.7% YoY
|
29.05
25.16 – 30.78
+8.5% YoY
|
32.79
32.11 – 33.27
+12.9% YoY
|
35.04
34.31 – 35.55
+6.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS International Sector Dividend Dogs ETF IDOG | 2.14% | 11.19M | 0.50% |
| 2 | iShares MSCI Denmark ETF EDEN | 2.00% | 4.11M | 0.53% |
| 3 | VanEck Morningstar International Moat ETF MOTI | 1.18% | 830.1K | 0.58% |
| 4 | Touchstone International Equity ETF TLCI | 1.16% | 1.20M | 1.00% |
| 5 | Franklin International Dividend Booster Index ETF XIDV | 0.81% | 358.5K | 0.19% |
| 6 | FlexShares International Quality Dividend Index Fund IQDF | 0.72% | 8.17M | 0.49% |
| 7 | iShares MSCI Europe Quality Dividend Advanced UCITS ETF EQDS.L | 0.67% | 6.38M | 0.28% |
| 8 | Fidelity Europe Quality Income UCITS ETF INC-EUR FEUI.L | 0.62% | 447.7K | 0.30% |
| 9 | Fidelity Europe Quality Income UCITS ETF ACC-EUR FEQD.L | 0.62% | 447.7K | 0.30% |
| 10 | Fidelity Europe Quality Income UCITS ETF ACC-GBP (hedged) FEQP.L | 0.62% | 524.8K | 0.35% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gavin Wood | President & Chief Executive Officer | 16M | male |
| Lars Soren Rasmussen | Interim CEO & President | 15M | male |
| Anders Lonning-Skovgaard | Executive Vice President & Chief Financial Officer | 8M | male |
| Allan Rasmussen | Executive Vice President of Global Operations | 5M | male |
| Nicolai Buhl Andersen | Executive Vice President of Chronic Care | 4M | male |
| Thomas Barfod | Senior Controller & Employees Representative Director | 500.0K | male |
| Dennis Kaysen | Vice President of Corporate Communications | — | male |
| Aleksandra Dimovska | Vice President of Investor Relations | — | — |
| Caroline Vagner Rosenstand | Executive Vice President of Chronic Care Commercial | — | female |
| Alain Morvan | Senior Vice President of Sales Europe | — | male |
| Mads Mikkelsen | VP of People & Culture - Chronic Care Commercial and Interim Head of Global People & Culture | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for COLO-B.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
